Immune response to enzyme replacement therapy: Single epitope control of antigen distribution from circulation

Molecular Genetics and Metabolism

Volumn 77, Issue 1-2, 2002, Pages 127-135

  Glaros, Elias N ^a,b   Turner, Chris T ^a   Parkinson, Emma J ^a   Hopwood, John J ^a   Brooks, Doug A ^a  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Antibodies; Epitopes; Genetic disease; Immune response; Therapy

Indexed keywords

EPITOPE; LEVO IDURONIDASE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGENICITY; ARTICLE; CIRCULATION; CONTROLLED STUDY; DRUG INFUSION; ENZYME REPLACEMENT; GENETIC DISORDER; HUMAN; HURLER SYNDROME; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; LYSOSOME STORAGE DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; AMINO ACID SEQUENCE; ANIMAL; DISEASE MODEL; ENZYMOLOGY; EPITOPE MAPPING; GENETICS; IMMUNOLOGY; LYSOSOME; METABOLISM; MOLECULAR GENETICS; MOUSE; SPRAGUE DAWLEY RAT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; EPITOPES; HUMANS; IDURONIDASE; IMMUNIZATION; LYSOSOMES; MICE; MOLECULAR SEQUENCE DATA; MUCOPOLYSACCHARIDOSIS I; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0036396627     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-7192(02)00148-8     Document Type: Article

References (37)

1. C. De Duve, From cytases to lysosomes, Fed. Proc. 23 (1964) 1045-1054.
2. E.F. Neufeld, J. Meunzer, The mucopolysaccharidoses, in: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.), The Metabolic Basis of Inherited Disease, McGraw-Hill, New York, 2001, pp. 3421-3452.
3. G.M. Pastores, A.R. Sibille, G.A. Grabowski, Enzyme therapy in Gaucher disease type I: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months, Blood 82 (1993) 408-416.
4. F. Giannelli, K.H. Choo, D.J. Rees, Y. Boyd, C.R. Rizza, G.G. Brownlee, Gene deletions in patients with hemophilia B and antifactor IX antibodies, Nature 303 (1983) 181-182.
5. E. Ponce, J. Moskovitz, G. Grabowski, Enzyme therapy in Gaucher disease type I: effect of neutralizing antibodies to acid β-glucosidase, Blood 90 (1997) 43-48.
6. D.A. Brooks, Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models, Mol. Genet. Metab. 68 (1999) 268-275.
7. E.C. Thorland, J.B. Drost, J.M. Lusher, I. Warrier, I. Shapiro, M.A. Koerper, D. Dimichele, J. Westman, N.S. Key, S.S. Somner, Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the greatest risk, Haemophilia 5 (1999) 101-105.
8. A.C. Crawley, D.A. Brooks, V.J. Muller, B.A. Petersen, E.L. Isaac, J. Bielicki, B.M. King, C.D. Boulter, A.J. Moore, N.L. Fazzalari, D.S. Anson, S. Byers, J.J. Hopwood, Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome, J. Clin. Inves. 97 (1996) 1864-1873.
9. D.A. Brooks, B.M. King, A.C. Crawley, S. Byers, J.J. Hopwood, Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models, Biochim. Biophys. Acta 1361 (1997) 203-216.
10. D.A. Brooks, J.J. Hopwood, B.M. King, Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model, Biochim. Biophys. Acta 1407 (1998) 163-172.
11. C.T. Turner, J.J. Hopwood, C.S. Bond, D.A. Brooks, Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats, Mol. Genet. Metab. 67 (1999) 194-205.
12. C.T. Turner, J.J. Hopwood, D.A. Brooks, Enzyme replacement therapy in mucopolysaccharidosis I: Altered distribution and targeting of α-L-iduronidase in immunized rats, Mol. Genet. Metab. 69 (2000) 277-285.
13. H.S. Scott, T. Litjens, J.J. Hopwood, C.P. Morris, A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype, Hum. Mutat. 1 (1992) 103-108.
14. H.S. Scott, T. Litjens, P.V. Nelson, D.A. Brooks, J.J. Hopwood, C.P. Morris, α-L-Iduronidase mutations (Q70X and P533R) associate with severe Hurler phenotypes, Hum. Mutat. 1 (1992) 333-339.
15. C.E. Beesley, C.A. Meaney, G. Greenland, V. Adams, A. Vellodi, E.P. Young, B.G. Winchester, Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations, Hum. Genet. 109 (2001) 503-511.
16. L.J. Ashton, D.A. Brooks, P.A. McCourt, V.J. Muller, P.R. Clements, J.J. Hopwood, Immunoquantification and enzyme kinetics of α-L-iduronidase in cultured fibroblasts from normal controls and mucopolysaccharidosis type I patients, Am. J. Hum. Genet. 50 (1992) 787-794.
17. D.A. Brooks, Review: the immunochemical analysis of enzyme from mucopolysaccharidoses patients, J. Inherit. Metab. Dis. 16 (1993) 3-15.
18. B. Henrissat, I. Callebaut, S. Fabrega, P. Lehn, J.P. Mornon, G. Davies, Conserved catalytic machinery and the prediction of a common fold for several families of glycosyl hydrolases, Proc. Natl. Acad. Sci. USA 92 (1995) 7090-7094.
19. B. Henrissat, G. Davies, Structural and sequence-based classification of glycoside hydrolases, Curr. Opin. Struct. Biol. 7 (1997) 637-644.
20. C.S. Bond, P.R. Clements, S.J. Ashby, C.A. Collyer, S.J. Harrop, J.J. Hopwood, J.M. Guss, Structure of a human lysosomal sulfatase, Structure 5 (1997) 277-289.
21. G. Lukatela, N. Krauss, K. Theis, T. Selmer, V. Gieselmann, K. von Figura, W. Saenger, Crystal structure of human arylsulfatase A - the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis, Biochem. 37 (1998) 3654-3664.
22. M.S. Sands, C. Vogler, J.W. Kyle, J.H. Grubb, B. Levy, N. Galvin, W.S. Sly, E.H. Birkenmeier, Enzyme replacement therapy for murine mucopolysaccharidoses type VII, J. Clin. Invest. 93 (1994) 2324-2331.
23. E.D. Kakkis, M.F. McEntee, A. Schmidtchen, E.F. Neufeld, D.A. Ward, R.E. Gompf, S. Kania, C. Bedolla, S.L. Chien, R.M. Shull, Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I, Biochem. Mol. Med. 58 (1996) 156-167.
24. N.W. Barton, R.O. Brady, J.M. Dambrosia, A.M. Di-Bisceglie, S.H. Doppelt, S.C. Hill, H.J. Mankin, G.J. Murray, R.I. Parker, C.E. Argo., R.P. Grewal, K. Yu, Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease, N. Engl. J. Med. 324 (1991) 1464-1470.
25. E. Beutler, Enzyme replacement therapy for Gaucher's disease, Bailliere's Clin. Haematol. 10 (1997) 751-763.
26. H. Van den Hout, A.J. Reuser, A.G. Vulto, M.C. Loonen, A. Cromme-Dijkhuis, A.T. Van der Ploeg, Recombinant human α-glucosidase from rabbit milk in Pompe patients, Lancet 356 (2000) 397-398.
27. E.D. Kakkis, J. Muenzer, G.E. Tiller, L. Waber, J. Belmont, M. Passage, B. Izykowski, J. Phillips, R. Doroshow, I. Walot, R. Hoft, E.F. Neufeld, Enzyme-replacement therapy in mucopolysaccharidosis I, N. Engl. J. Med. 344 (2001) 182-188.
28. M. Rosenberg, W. Kingma, M.A. Fitzpatrick, S.M. Richards, Immunosurveillence of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeated administration, Blood 93 (1999) 2081-2088.
29. D.A. Brooks, T.M. Bradford, J.J. Hopwood, An improved method for the purification of IgG monoclonal antibodies from culture supernatants, J. Immunol. Meth. 155 (1992) 129-132.
30. P.R. Clements, D.A. Brooks, P.A.G. McCourt, J.J. Hopwood, Immunopurification and characterisation of human α-L-iduronidase with the use of monoclonal antibodies, Biochem. J. 259 (1989) 199-208.
31. H.M. Geysen, R.H. Meloen, S.J. Barteling, Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid, Proc. Natl. Acad. Sci. USA 81 (1984) 3998-4002.
32. C.M. Eng, N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, S. Waldek, L. Caplan, G.E. Linthorst, R.J. Desnick, Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease, N. Engl. J. Med. 345 (2001) 9-16.
33. S. Lehrman, Virus treatment questioned after gene therapy death, Nature 401 (1999) 517-518.
34. H.S. Scott, D.S. Anson, A.M. Osborne, P.V. Nelson, P.R. Clements, C.P. Morris, J.J. Hopwood, Human α-L-iduronidase: cDNA isolation and expression, Proc. Natl. Acad. Sci. USA 88 (1991) 9695-9699.
35. D.A. Brooks, S. Fabrega, L.K. Hein, E.J. Parkinson, P. Durand, G. Yogalingam, U. Matte, R. Giugliani, A. Dasvarma, J. Eslahpazire, B. Henrissat, J.-P. Mornon, J.J. Hopwood, P. Lehn, Glycosidase active site mutations in human α-L-iduronidase, Glycobiology 11 (2001) 741-750.
36. K.-W. Zhao, K.F. Faull, E.D. Kakkis, E.F. Neufeld, Carbohydrate structures of recombinant human α-L-iduronidase secreted by Chinese hamster ovary cells, J. Biol. Chem. 272 (1997) 22758-22765.
37. L.E. Guagliardi, B. Koppelman, J.S. Blum, M.S. Marks, P. Creswell, F.M. Brodsky, Co-localisation of molecules involved in antigen processing and presentation in an early endocytic compartment, Nature 343 (1990) 133-139.